Text Size

Role of Epicardial Adipose Tissue in Coronary Artery Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by McMaster University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Heart and Stroke Foundation of Canada
Information provided by:
McMaster University
ClinicalTrials.gov Identifier:
NCT00279227
First received: January 17, 2006
Last updated: August 9, 2006
Last verified: January 2006
History of Changes
  Purpose

We sight to evaluate whether patients with coronary artery disease (CAD) have more epicardial fat than patients without CAD, which would suggest that epicardial fat may be more than an “innocent bystander” and be actively involved in the disease process. Its role as a modulator of vascular response and myocardial function could potentially lead to new areas of cardiac research. We also sight to evaluate whether epicardial fat from patients with CAD releases more adipokines than subcutaneous fat from these patients which could prompt studies into the differential regulation of adipokine secretion in this tissue. Thus for e.g., the use of thiazolidinediones (glitazones), statins, ARBs or other compounds that can specifically modulate adipokine secretion could be explored to determine their benefit in ameliorating the effects attributable to increased epicardial fat.


Condition
Coronary Artery Disease
Obesity

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Role of Epicardial Adipose Tissue in Coronary Artery Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by McMaster University:

Estimated Enrollment: 50
Study Start Date: January 2006
Estimated Study Completion Date: December 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients elegible for elective cardiac surgery are elegible
  • Ability to provide written informed consent in accordance with GCP guidelines and local legislations.
  • > 18 years of age

Exclusion Criteria:

  • Control patients will not have clinical signs of CAD and will show normal coronary arteries on angiography.
  • Any medical, social or geographic condition, which, in the opinion of the investigator would not allow safe or reliable completion of the protocol.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00279227

Contacts
Contact: Suzana Damjanovic, MLT, CCRA 905-527-4322 ext 44710 suzana@cardio.on.ca

Locations
Canada, Ontario
Hamilton Health Sciences - Cardiovascular Obesity Research and Management Center Recruiting
Hamilton, Ontario, Canada, L8L 2X2
Sub-Investigator: Gianluca Iacobellis, MD PhD            
Principal Investigator: Arya M Sharma, MD FRCPC            
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Heart and Stroke Foundation of Canada
Investigators
Principal Investigator: Arya M Sharma, MD, FRCPC McMaster University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00279227     History of Changes
Other Study ID Numbers: EPICARD Study
Study First Received: January 17, 2006
Last Updated: August 9, 2006
Health Authority: Canada: Health Canada

Keywords provided by McMaster University:
coronary artery disease
epicardial adipose tissue
epicardial fat
obesity

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Obesity
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
 Arterial Occlusive Diseases
Vascular Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on May 19, 2013